Cargando…

Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review

The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrine tumors (NETs) of the GastroEnteroPancreatic-(GEP-) system depending on tumor primary location and meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Nölting, Svenja, Kuttner, Axel, Lauseker, Michael, Vogeser, Michael, Haug, Alexander, Herrmann, Karin A., Hoffmann, Johannes N., Spitzweg, Christine, Göke, Burkhard, Auernhammer, Christoph J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712684/
https://www.ncbi.nlm.nih.gov/pubmed/24213232
http://dx.doi.org/10.3390/cancers4010141
_version_ 1782277099305828352
author Nölting, Svenja
Kuttner, Axel
Lauseker, Michael
Vogeser, Michael
Haug, Alexander
Herrmann, Karin A.
Hoffmann, Johannes N.
Spitzweg, Christine
Göke, Burkhard
Auernhammer, Christoph J.
author_facet Nölting, Svenja
Kuttner, Axel
Lauseker, Michael
Vogeser, Michael
Haug, Alexander
Herrmann, Karin A.
Hoffmann, Johannes N.
Spitzweg, Christine
Göke, Burkhard
Auernhammer, Christoph J.
author_sort Nölting, Svenja
collection PubMed
description The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrine tumors (NETs) of the GastroEnteroPancreatic-(GEP-) system depending on tumor primary location and metastatic spread. In a retrospective single-center series, sensitivities were evaluated in serum samples from 110 patients with midgut (n = 62) and pancreatic (n = 48) NETs. CgA levels were analyzed by a commercially-available immunoradiometric assay (CIS-bio) during routine follow-up in the years 2000–2009. CgA showed a higher sensitivity for midgut (68%) than pancreatic (54%) NETs. A higher CgA sensitivity and significantly higher median CgA values were found in patients with liver metastases than in those without, and in patients with hepatic and additionally extra-hepatic metastases than in those with hepatic and nodal metastases alone, respectively. We found an overall sensitivity for elevated 5HIAA excretion of 69% for midgut NETs and a significant correlation between median CgA and 5-HIAA values. The sensitivity of AP and the correlations of AP/CgA-data-pairs were low in both midgut and pancreatic NETs, although highest for metastatic pancreatic NETs. The sensitivity of CgA measurement depends on the NET primary location and spread of disease. 5-HIAA and CgA showed comparable sensitivity in midgut NETs, while AP does not seem to be useful as a tumor marker in GEP-NETs.
format Online
Article
Text
id pubmed-3712684
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-37126842013-08-05 Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review Nölting, Svenja Kuttner, Axel Lauseker, Michael Vogeser, Michael Haug, Alexander Herrmann, Karin A. Hoffmann, Johannes N. Spitzweg, Christine Göke, Burkhard Auernhammer, Christoph J. Cancers (Basel) Article The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrine tumors (NETs) of the GastroEnteroPancreatic-(GEP-) system depending on tumor primary location and metastatic spread. In a retrospective single-center series, sensitivities were evaluated in serum samples from 110 patients with midgut (n = 62) and pancreatic (n = 48) NETs. CgA levels were analyzed by a commercially-available immunoradiometric assay (CIS-bio) during routine follow-up in the years 2000–2009. CgA showed a higher sensitivity for midgut (68%) than pancreatic (54%) NETs. A higher CgA sensitivity and significantly higher median CgA values were found in patients with liver metastases than in those without, and in patients with hepatic and additionally extra-hepatic metastases than in those with hepatic and nodal metastases alone, respectively. We found an overall sensitivity for elevated 5HIAA excretion of 69% for midgut NETs and a significant correlation between median CgA and 5-HIAA values. The sensitivity of AP and the correlations of AP/CgA-data-pairs were low in both midgut and pancreatic NETs, although highest for metastatic pancreatic NETs. The sensitivity of CgA measurement depends on the NET primary location and spread of disease. 5-HIAA and CgA showed comparable sensitivity in midgut NETs, while AP does not seem to be useful as a tumor marker in GEP-NETs. MDPI 2012-02-15 /pmc/articles/PMC3712684/ /pubmed/24213232 http://dx.doi.org/10.3390/cancers4010141 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Nölting, Svenja
Kuttner, Axel
Lauseker, Michael
Vogeser, Michael
Haug, Alexander
Herrmann, Karin A.
Hoffmann, Johannes N.
Spitzweg, Christine
Göke, Burkhard
Auernhammer, Christoph J.
Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
title Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
title_full Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
title_fullStr Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
title_full_unstemmed Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
title_short Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
title_sort chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712684/
https://www.ncbi.nlm.nih.gov/pubmed/24213232
http://dx.doi.org/10.3390/cancers4010141
work_keys_str_mv AT noltingsvenja chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT kuttneraxel chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT lausekermichael chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT vogesermichael chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT haugalexander chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT herrmannkarina chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT hoffmannjohannesn chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT spitzwegchristine chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT gokeburkhard chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview
AT auernhammerchristophj chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview